Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 10Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Carcinoma, Renal Cell 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myeloproliferative Disorders 3Lung Neoplasms 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Neuroblastoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3aflibercept 2Trastuzumab 2Specimen Handling 2Cisplatin 2Carboplatin 2vinflunine 1tipifarnib 1erdafitinib 1enzalutamide 1entinostat 1enfortumab vedotin 1cabozantinib 1avelumab 1Thalidomide 1Sorafenib 1Ramucirumab 1Radiotherapy 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Introns 1Interleukin-12 Subunit p35 1Interleukin-12 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urethral Neoplasms × CTLA-4 Antigen × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡